Search results
Results from the WOW.Com Content Network
The Common Terminology Criteria for Adverse Events (CTCAE), [1] formerly called the Common Toxicity Criteria (CTC or NCI-CTC), are a set of criteria for the standardized classification of adverse events of drugs and treatment used in cancer therapy. The CTCAE system is a product of the US National Cancer Institute (NCI).
The severity of oral mucositis can be evaluated using several different assessment tools. Two of the most commonly used are the World Health Organization (WHO) Oral Toxicity score [9] and the National Cancer Institute Common Toxicity Criteria (NCI-CTC) for Oral Mucositis. [10]
Six types of toxicity data are included in the file: Primary irritation; Mutagenic effects; Reproductive effects; Tumorigenic effects; Acute toxicity; Other multiple dose toxicity; Specific numeric toxicity values such as LD 50, LC 50, TDLo, and TCLo are noted as well as species studied and the route of administration used. For all data the ...
Pages for logged out editors learn more. Contributions; Talk; Common Toxicity Criteria
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (as described in the American Academy of Audiology Ototoxicity Monitoring Guidelines from 2009): [8] Grade 1: Threshold shift or loss of 15-25 dB relative to baseline, averaged at two or more contiguous frequencies in at least one ear
DTP/NCI DTP Open Compound collection National Cancer Institute Development Therapeutics Program Cancer therapeutics Cancer Chemotherapy National Service Center number "DTP/NCI". 250,000 ECHA: REACH database: European Chemicals Agency: EINECS ELINCS NLP: CASNo HPhrases pictograms tonnage "ECHA/REACH". 245,000 EAWAG-BBD Biocatalysis ...
Serious adverse reactions are serious adverse events judged to be related to drug therapy. A SUSAR (suspected unexpected serious adverse reaction) should be reported to a drug regulatory authority under an investigational license by using the CIOMS form (or in some countries an equivalent form).
Racotumomab is well tolerated by patients. The overall toxicity of the vaccine has been classified as grade 1 and 2, according to the NCI Common Toxicity Criteria (version 3.0). Treatment is mostly associated with mild to moderate injection site reactions (local erythema, induration and pain), which disappear within 24–48 hours. Systemic ...